Table 1.
The baseline demographic and disease characteristics of the study cohort
| Patient Characteristics | Non-biologic cohort (n = 3,421) | Etanercept (n = 1,352) | Adalimumab (n = 3,271) | Ustekinumab (n = 994) |
|---|---|---|---|---|
| Demographics | ||||
| Age in years, mean (SD) | 44.6 (14.0) | 45.5 (12.9) | 44.7 (12.5) | 45.9 (13.2) |
| Female | 1489 (43.5) | 565 (41.8) | 1323 (40.4) | 377 (37.9) |
| Waist circumference in cm, mean (SD) | 99.7 (17.1) | 101.7 (16.6) | 101.2 (16.8) | 104.7 (19.0) |
| BMI category, n (%) | ||||
| Underweight (<18.5 kg/m2) | 43 (1.3) | 17 (1.3) | 22 (0.7) | 8 (0.8) |
| Normal (18.5–24.9 kg/m2) | 677 (19.8) | 236 (17.5) | 546 (16.7) | 149 (15.0) |
| Overweight (25.0–29.9 kg/m2) | 1071 (31.3) | 408 (30.2) | 1031 (31.5) | 262 (26.4) |
| Obese I (30.0–34.9 kg/m2) | 735 (21.5) | 296 (21.9) | 787 (24.1) | 211 (21.2) |
| Obese II (35.0–39.9 kg/m2) | 345 (10.1) | 178 (13.2) | 381 (11.6) | 141 (14.2) |
| Obese III (≥40 kg/m2) | 279 (8.2) | 107 (7.9) | 275 (8.4) | 141 (14.2) |
| Comorbidities and risk factors1 | ||||
| No comorbidity | 1323 (38.7) | 377 (27.9) | 1016 (31.1) | 323 (32.5) |
| 1–2 comorbidities | 1585 (46.3) | 689 (51.0) | 1636 (50.0) | 436 (43.9) |
| 3–4 comorbidities | 416 (12.2) | 233 (17.2) | 513 (15.7) | 178 (17.9) |
| ≥5 comorbidities | 97 (2.8) | 53 (3.9) | 106 (3.2) | 57 (5.7) |
| Hypertension | 620 (18.1) | 390 (28.8) | 782 (23.9) | 259 (26.1) |
| Past TB | 21 (0.6) | 22 (1.6) | 29 (0.9) | 8 (0.8) |
| Diabetes mellitus | 254 (7.4) | 135 (10.0) | 251 (7.7) | 112 (11.3) |
| Dyslipidemia | 307 (9.0) | 143 (10.6) | 334 (10.2) | 120 (12.1) |
| Asthma | 361 (10.6) | 137 (10.1) | 340 (10.4) | 120 (12.1) |
| COPD | 69 (2.0) | 17 (1.3) | 45 (1.4) | 26 (2.6) |
| Immunodeficiency syndromes | 6 (0.2) | 4 (0.3) | 1 (0.0) | 4 (0.4) |
| Number of cigarettes smoked per day, mean (SD) | 4.6 (7.7) | 4.0 (7.1) | 3.8 (6.8) | 3.8 (7.1) |
| Alcohol units per week, mean (SD) | 7.7 (12.1) | 9.4 (17.1) | 8.4 (13.4) | 7.7 (12.8) |
| Disease | ||||
| Disease duration in years, median (IQR) | 18.0 (18.0) | 21.0 (18.0) | 20.0 (17.0) | 20.0 (19.0) |
| Baseline PASI score, median (IQR) | 14.1 (7.9) | 13.8 (7.8) | 14.3 (8.6) | 14.6 (8.1) |
| Inflammatory arthritis | 363 (10.6) | 316 (23.4) | 819 (25.0) | 158 (15.9) |
| Concomitant treatments, n (%) | ||||
| Any exposure to methotrexate during follow-up | 2,118 (61.9) | 229 (16.9) | 572 (17.5) | 83 (8.4) |
| Any exposure to cyclosporine during follow-up | 1,216 (35.6) | 104 (7.7) | 225 (6.9) | 38 (3.8) |
| Any exposure to acitretin during follow-up | 970 (28.4) | 48 (3.6) | 71 (2.2) | 27 (2.7) |
| Any exposure to fumaric acid esters during follow-up | 552 (16.1) | 26 (1.9) | 30 (0.9) | 5 (0.5) |
| Any exposure to hydroxycarbamide during follow-up | 56 (1.6) | 6 (0.4) | 17 (0.5) | 10 (1.0) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; PASI, Psoriasis Area and Severity Score; SD, standard deviation; TB, tuberculosis.
1
List of predefined comorbidities includes hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcer disease, chronic renal disease, liver disease, previous tuberculosis, demyelination, diabetes mellitus, impaired glucose tolerance, depression, dyslipidemia, nonskin cancer, immunodeficiency syndromes, and thyroid disease.